Inventiva(US:IVA) Globenewswireยท2025-01-22 21:00Core Insights - Inventiva, a clinical-stage biopharmaceutical company, is focused on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [1][5][6] - The results from the Proof-of-Concept trial evaluating lanifibranor in combination with empagliflozin for treating MASH will be presented at the Steatotic Liver Disease Summit 2025 [1][2] Study Details - The LEGEND trial is a multi-center, randomized, placebo-controlled Phase II Proof-of-Concept study assessing the safety and efficacy of lanifibranor (800mg once daily) combined with empagliflozin over a 24-week treatment period in patients with non-cirrhotic MASH and type-2 diabetes (T2D) [2] - The study met its primary efficacy endpoint, showing a significant reduction in HbA1c levels in both the lanifibranor and combination arms compared to placebo [3] - Secondary endpoints also demonstrated therapeutic efficacy, including improvements in liver injury markers, glucose and lipid metabolism, and hepatic steatosis, with no weight gain observed in patients receiving the combination treatment [3] Presentation Details - The abstract titled "The combination of lanifibranor with empagliflozin further enhances metabolic improvement in patients with MASH and T2D" will be presented by Dr. Onno Holleboom on January 25, 2025 [4] Company Overview - Inventiva is advancing its lead product candidate, lanifibranor, which is currently in a pivotal Phase III clinical trial (NATiV3) for treating adult patients with MASH [6] - The company has a pipeline that includes odiparcil for treating adult MPS VI patients, although clinical efforts for odiparcil have been suspended as Inventiva focuses on lanifibranor [7] - Inventiva has a scientific team of approximately 90 people and owns a library of around 240,000 pharmacologically relevant molecules, with about 60% being proprietary [8]